Evidence map›Paper›PMID 29660503›Full record

ArticleRedox biology2018

High circulatory leptin mediated NOX-2-peroxynitrite-miR21 axis activate mesangial cells and promotes renal inflammatory pathology in nonalcoholic fatty liver disease.

Firas Alhasson, Ratanesh Kumar Seth, Sutapa Sarkar, Diana A Kimono, Muayad S Albadrani, Diptadip Dattaroy, Varun Chandrashekaran, Geoffrey I Scott, Samir Raychoudhury, Mitzi Nagarkatti and 3 more

Open access · goldAbstract read
In one paragraph

Article in Redox biology, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 16 papers.

0numbers the graph read from it
0cells of the map it votes in
16citing papers in PubMed
3.2field-weighted citation impact, top 8% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

16 citing papers in PubMed, 35 citations in OpenAlex.

  1. Review
  2. Review
  3. Research (Washington, D.C.) · 2025
    Article
  4. Article
  5. Article
  6. P16Oxidative medicine and cellular longevity · 2023
    Article
  7. Article
  8. Article
  9. Article
  10. Article
  11. Article
  12. Article
  13. Review
  14. Five Constituents inFrontiers in pharmacology · 2019
    Article
  15. Article
  16. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors at 4 institutions in 1 country.

Firas AlhassonEnvironmental Health and Disease Laboratory, Department of Environmental Health Sciences, Arnold School of Public Health, University of South Carolina, Columbia, SC, USA.
Ratanesh Kumar SethEnvironmental Health and Disease Laboratory, Department of Environmental Health Sciences, Arnold School of Public Health, University of South Carolina, Columbia, SC, USA.
Sutapa SarkarEnvironmental Health and Disease Laboratory, Department of Environmental Health Sciences, Arnold School of Public Health, University of South Carolina, Columbia, SC, USA.
Diana A KimonoEnvironmental Health and Disease Laboratory, Department of Environmental Health Sciences, Arnold School of Public Health, University of South Carolina, Columbia, SC, USA.
Muayad S AlbadraniEnvironmental Health and Disease Laboratory, Department of Environmental Health Sciences, Arnold School of Public Health, University of South Carolina, Columbia, SC, USA.
Diptadip DattaroyEnvironmental Health and Disease Laboratory, Department of Environmental Health Sciences, Arnold School of Public Health, University of South Carolina, Columbia, SC, USA.
Varun ChandrashekaranEnvironmental Health and Disease Laboratory, Department of Environmental Health Sciences, Arnold School of Public Health, University of South Carolina, Columbia, SC, USA.
Geoffrey I ScottEnvironmental Health and Disease Laboratory, Department of Environmental Health Sciences, Arnold School of Public Health, University of South Carolina, Columbia, SC, USA.
Samir RaychoudhuryDepartment of Biology, Chemistry and Environmental Health Science, Benedict College, Columbia, SC 29204, USA.
Mitzi NagarkattiDepartment of Pathology, Microbiology and Immunology, University of South Carolina School of Medicine, Columbia, SC, USA.
Prakash NagarkattiDepartment of Pathology, Microbiology and Immunology, University of South Carolina School of Medicine, Columbia, SC, USA.
Anna Mae DiehlDivision of Gastroenterology, Duke University, Durham, NC 27707, USA.
Saurabh ChatterjeeEnvironmental Health and Disease Laboratory, Department of Environmental Health Sciences, Arnold School of Public Health, University of South Carolina, Columbia, SC, USA. Electronic address: schatt@mailbox.sc.edu.
South Carolina Department of Health and Environmental Control · USUniversity of South Carolina · USBenedict College · USDuke University · US

Funding

Targeting early ceramide elevation in pre-symptomatic eczemaP20GM103641 · NIGMS · UNIVERSITY OF SOUTH CAROLINA AT COLUMBIA · PI ENOS, REILLY, NAGARKATTI, PRAKASH S · 2012 to 2023
$20.7M
Use of Resveratrol to treat experimental multiple sclerosisP01AT003961 · NCCIH · UNIVERSITY OF SOUTH CAROLINA AT COLUMBIA · PI NAGARKATTI, PRAKASH S · 2007 to 2018
$14.2M
LIVER DISEASE IN OBESITYR01DK053792 · NIDDK · JOHNS HOPKINS UNIVERSITY · PI DIEHL, ANNA MAE ELIZABETH · 1999 to 2013
$3.6M
Role of natural indoles in experimental autoimmune encephalomyelitisR01AT006888 · NCCIH · UNIVERSITY OF SOUTH CAROLINA AT COLUMBIA · PI NAGARKATTI, MITZI · 2011 to 2015
$2.0M
AhR ligands in epigenetic dysregulation of T cellsR01AI123947 · NIAID · UNIVERSITY OF SOUTH CAROLINA AT COLUMBIA · PI NAGARKATTI, MITZI, NAGARKATTI, PRAKASH S · 2017 to 2021
$1.8M
Immunopathological basis of PTSDR01MH094755 · NIMH · UNIVERSITY OF SOUTH CAROLINA AT COLUMBIA · PI NAGARKATTI, PRAKASH S · 2011 to 2015
$1.7M
Estrogen-T cell InteractionsR01ES019313 · NIEHS · UNIVERSITY OF SOUTH CAROLINA AT COLUMBIA · PI NAGARKATTI, MITZI, NAGARKATTI, PRAKASH S · 2010 to 2014
$1.5M
Free Radical Mechanism in Obesity Potentiation of Environmental HepatotoxicityR00ES019875 · NIEHS · UNIVERSITY OF SOUTH CAROLINA AT COLUMBIA · PI CHATTERJEE, SAURABH · 2012 to 2014
$747k
Role of CD44 in experimental Multiple SclerosisI01BX001357 · VA · VETERANS HEALTH ADMINISTRATION · PI NAGARKATTI, MITZI · 2012 to 2015
–
BLRD VA I01 BX001357NCCIH NIH HHS P01 AT003961NCCIH NIH HHS R01 AT006888NIAID NIH HHS R01 AI123947NIDDK NIH HHS R01 DK053792NIEHS NIH HHS R00 ES019875NIEHS NIH HHS R01 ES019313NIGMS NIH HHS P20 GM103641NIMH NIH HHS R01 MH094755
6 · The paper itself

Abstract

High circulatory insulin and leptin followed by underlying inflammation are often ascribed to the ectopic manifestations in non-alcoholic fatty liver disease (NAFLD) but the exact molecular pathways remain unclear. We have shown previously that CYP2E1-mediated oxidative stress and circulating leptin in NAFLD is associated with renal disease severity. Extending the studies, we hypothesized that high circulatory leptin in NAFLD causes renal mesangial cell activation and tubular inflammation via a NOX2 dependent pathway that upregulates proinflammatory miR21. High-fat diet (60% kcal) was used to induce fatty liver phenotype with parallel insulin and leptin resistance. The kidneys were probed for mesangial cell activation and tubular inflammation that showed accelerated NASH phenotype and oxidative stress in the liver. Results showed that NAFLD kidneys had significant increases in α-SMA, a marker of mesangial cell activation, miR21 levels, tyrosine nitration and renal inflammation while they were significantly decreased in leptin and p47 phox knockout mice. Micro RNA21 knockout mice showed decreased tubular immunotoxicity and proinflammatory mediator release. Mechanistically, use of NOX2 siRNA or apocynin,phenyl boronic acid (FBA), DMPO or miR21 antagomir inhibited leptin primed-miR21-mediated mesangial cell activation in vitro suggesting a direct role of leptin-mediated NOX-2 in miR21-mediated mesangial cell activation. Finally, JAK-STAT inhibitor completely abrogated the mesangial cell activation in leptin-primed cells suggesting that leptin signaling in the mesangial cells depended on the JAK-STAT pathway. Taken together the study reports a novel mechanistic pathway of leptin-mediated renal inflammation that is dependent on NOX-2-miR21 axis in ectopic manifestations underlying NAFLD-induced co-morbidities.

Indexed as

AnimalsATPases Associated with Diverse Cellular ActivitiesDiet, High-FatDNA HelicasesHumansInflammationJanus KinasesKidneyLeptinMesangial CellsMiceMice, KnockoutMicroRNAsNADPH Oxidase 2Non-alcoholic Fatty Liver DiseaseOxidative StressATPases Associated with Diverse Cellular ActivitiesCybb protein, mouseDNA HelicasesJanus KinasesLeptinMicroRNAsMIRN21 microRNA, mouseNADPH Oxidase 2Peroxynitrous AcidRUVBL2 protein, mouseSTAT Transcription FactorsJAK/STATLeptinMesangial cellsmiR21NADPHNAFLDNOX-2Oxidative stresssiRNA

Identifiers

PMID29660503
PMCPMC6006523
OpenAlexW2796239046

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.